[4] Among the participants who proceeded to surgery, those with positive readings in the pelvic lymph nodes on piflufolastat (18F) PET had a clinically important rate of metastatic cancer confirmed by surgical pathology.

[4] Prior to a single piflufolastat (18F) PET/CT scan, all of these participants had baseline conventional imaging performed that did not show definite spread of prostate cancer.

[4] In participants with positive piflufolastat (18F) PET readings who had correlative tissue pathology from biopsies, results from baseline or follow-up imaging by conventional methods, or serial PSA levels available for comparison, local recurrence or metastasis of prostate cancer was confirmed in an estimated 85% to 87% of cases, depending on the reader.

[4] Thus, the second trial demonstrated that piflufolastat (18F) PET can detect sites of disease in participants with biochemical evidence of recurrent prostate cancer, thereby providing important information that may impact the approach to therapy.

[7] The US Food and Drug Administration (FDA) granted approval of Pylarify to Progenics Pharmaceuticals, Inc.[4] This article incorporates public domain material from the United States Department of Health and Human Services